Selected research
Industry Research
Cancer Biopharmaceuticals Industry Research Report 2026
Market perspective
The global Cancer Biopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cancer Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cancer Biopharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cancer Biopharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Novartis, Merck, Mylan, Eli Lilly, Pfizer, GlaxoSmithKline and AstraZeneca, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cancer Biopharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cancer Biopharmaceuticals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Biopharmaceuticals Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Mylan
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
LEO Pharma
Elusys Therapeutics
Bristol-Myers Squibb
Boehringer Ingelheim
Alexion Pharmaceuticals
Agios Pharmaceuticals
Cancer Biopharmaceuticals Segment by Type
Biologics
Biosimilars
Cancer Biopharmaceuticals Segment by Application
Liquid Cancers
Solid Cancers
Cancer Biopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cancer Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilars
Applications
- Liquid Cancers
- Solid Cancers
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Mylan
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- LEO Pharma
- Elusys Therapeutics
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Agios Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cancer Biopharmaceuticals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biologics
- 2.2.3 Biosimilars
- 2.3 Cancer Biopharmaceuticals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Liquid Cancers
- 2.3.3 Solid Cancers
- 2.4 Assumptions and Limitations
3 Cancer Biopharmaceuticals Breakdown Data by Type
- 3.1 Global Cancer Biopharmaceuticals Historic Market Size by Type (2021-2026)
- 3.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Cancer Biopharmaceuticals Breakdown Data by Application
- 4.1 Global Cancer Biopharmaceuticals Historic Market Size by Application (2021-2026)
- 4.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cancer Biopharmaceuticals Market Perspective (2021-2032)
- 5.2 Global Cancer Biopharmaceuticals Growth Trends by Region
- 5.2.1 Global Cancer Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cancer Biopharmaceuticals Historic Market Size by Region (2021-2026)
- 5.2.3 Cancer Biopharmaceuticals Forecasted Market Size by Region (2027-2032)
- 5.3 Cancer Biopharmaceuticals Market Dynamics
- 5.3.1 Cancer Biopharmaceuticals Industry Trends
- 5.3.2 Cancer Biopharmaceuticals Market Drivers
- 5.3.3 Cancer Biopharmaceuticals Market Challenges
- 5.3.4 Cancer Biopharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cancer Biopharmaceuticals Players by Revenue
- 6.1.1 Global Top Cancer Biopharmaceuticals Players by Revenue (2021-2026)
- 6.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2021-2026)
- 6.2 Global Cancer Biopharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cancer Biopharmaceuticals Head Office and Area Served
- 6.4 Global Cancer Biopharmaceuticals Players, Product Type & Application
- 6.5 Global Cancer Biopharmaceuticals Manufacturers Established Date
- 6.6 Global Cancer Biopharmaceuticals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cancer Biopharmaceuticals Market Size (2021-2032)
- 7.2 North America Cancer Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 7.4 North America Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cancer Biopharmaceuticals Market Size (2021-2032)
- 8.2 Europe Cancer Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 8.4 Europe Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cancer Biopharmaceuticals Market Size (2021-2032)
- 9.2 Asia-Pacific Cancer Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cancer Biopharmaceuticals Market Size (2021-2032)
- 10.2 South America Cancer Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 10.4 South America Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cancer Biopharmaceuticals Market Size (2021-2032)
- 11.2 Middle East & Africa Cancer Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.1.4 Sanofi Cancer Biopharmaceuticals Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.2.4 Johnson & Johnson Cancer Biopharmaceuticals Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.3.4 Novartis Cancer Biopharmaceuticals Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.4.4 Merck Cancer Biopharmaceuticals Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Mylan
- 12.5.1 Mylan Company Information
- 12.5.2 Mylan Business Overview
- 12.5.3 Mylan Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.5.4 Mylan Cancer Biopharmaceuticals Product Portfolio
- 12.5.5 Mylan Recent Developments
- 12.6 Eli Lilly
- 12.6.1 Eli Lilly Company Information
- 12.6.2 Eli Lilly Business Overview
- 12.6.3 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.6.4 Eli Lilly Cancer Biopharmaceuticals Product Portfolio
- 12.6.5 Eli Lilly Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.7.4 Pfizer Cancer Biopharmaceuticals Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 GlaxoSmithKline
- 12.8.1 GlaxoSmithKline Company Information
- 12.8.2 GlaxoSmithKline Business Overview
- 12.8.3 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.8.4 GlaxoSmithKline Cancer Biopharmaceuticals Product Portfolio
- 12.8.5 GlaxoSmithKline Recent Developments
- 12.9 AstraZeneca
- 12.9.1 AstraZeneca Company Information
- 12.9.2 AstraZeneca Business Overview
- 12.9.3 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.9.4 AstraZeneca Cancer Biopharmaceuticals Product Portfolio
- 12.9.5 AstraZeneca Recent Developments
- 12.10 LEO Pharma
- 12.10.1 LEO Pharma Company Information
- 12.10.2 LEO Pharma Business Overview
- 12.10.3 LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.10.4 LEO Pharma Cancer Biopharmaceuticals Product Portfolio
- 12.10.5 LEO Pharma Recent Developments
- 12.11 Elusys Therapeutics
- 12.11.1 Elusys Therapeutics Company Information
- 12.11.2 Elusys Therapeutics Business Overview
- 12.11.3 Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.11.4 Elusys Therapeutics Cancer Biopharmaceuticals Product Portfolio
- 12.11.5 Elusys Therapeutics Recent Developments
- 12.12 Bristol-Myers Squibb
- 12.12.1 Bristol-Myers Squibb Company Information
- 12.12.2 Bristol-Myers Squibb Business Overview
- 12.12.3 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.12.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Product Portfolio
- 12.12.5 Bristol-Myers Squibb Recent Developments
- 12.13 Boehringer Ingelheim
- 12.13.1 Boehringer Ingelheim Company Information
- 12.13.2 Boehringer Ingelheim Business Overview
- 12.13.3 Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Product Portfolio
- 12.13.5 Boehringer Ingelheim Recent Developments
- 12.14 Alexion Pharmaceuticals
- 12.14.1 Alexion Pharmaceuticals Company Information
- 12.14.2 Alexion Pharmaceuticals Business Overview
- 12.14.3 Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 12.14.5 Alexion Pharmaceuticals Recent Developments
- 12.15 Agios Pharmaceuticals
- 12.15.1 Agios Pharmaceuticals Company Information
- 12.15.2 Agios Pharmaceuticals Business Overview
- 12.15.3 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2021-2026)
- 12.15.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 12.15.5 Agios Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst